Sun Pharma Fires Back At Biovail In Cardizem Suit

Law360, New York (November 19, 2008, 12:00 AM EST) -- Indian generics maker Sun Pharmaceutical Industries Ltd. has accused Biovail Laboratories International SRL of violating antitrust laws and misleading the U.S. Patent and Trademark Office in a new set of counterclaims regarding patents for the hypertension drug Cardizem.

Sun lodged a slew of counterclaims in the U.S. District Court for the District of New Jersey on Tuesday in an attempt to invalidate three of Biovail's patents for various ingredients in Cardizem, the brand name for diltiazem.

Biovail initially targeted Sun in a lawsuit filed in August...
To view the full article, register now.